Profile: GlycoMimetics, Inc. specializes in the rational design of small molecule therapeutics that mimic the functions of bioactive carbohydrates. We develop drug candidates with a focus on inflammation, cancer and infectious disease. We develop small molecular weight compound known as GMI-1051 for the treatment or prevention of infections caused by pseudomonas aeruginosa, a bacterium responsible for an increasing number of infections which are frequently refractory to treatment with antibiotics.